ReviewCell2020
The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution.
Open access · hybridAbstract readReview
In one paragraph
Review in Cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 358 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
358citing papers in PubMed, 1 pooled it
28.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
358 citing papers in PubMed, 1 synthesis or guideline pooled it, 574 citations in OpenAlex.
- Applications and challenges of biomarker-based predictive models in proactive health management.Frontiers in public health · 2025Pooled it
- Integrating multi-omics data for next-generation cancer research and precision medicine.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Decoding epithelial-mesenchymal transitions with multi-omics.Nature reviews. Genetics · 2026Review
- 3D multi-omics tumour atlases: from technology to biology and clinical translation.Nature reviews. Cancer · 2026Review
- Spatial Integration of Protein and Chromosomal States Reveals Early Copy-Number Changes and Genotype-Associated Immune Neighborhoods in Serous Ovarian Cancer Evolution.Cancer discovery · 2026Article
- Data-centric feedback loops for next-generation immunotherapy development.Nature biomedical engineering · 2026Review
- HuBMAP Data Portal: a resource for multimodal spatial and single-cell data of healthy human tissues.ArXiv · 2026Article
- Development of a universal imaging "phenome" using shape, appearance and motion (SAM) features and the SAM Phenotype Observation Tool (SPOT).Nature communications · 2026Article
- Spatial omics illuminates tumor heterogeneity.Cell reports methods · 2026Review
- SpatioTemporal Omics Consortium: a global effort for biological discovery across species, space and time.Nature methods · 2026Article
- NicheTrans: spatial-aware cross-omics translation.Nature methods · 2026Article
- Spatium: A Protein Language Foundation Model for Spatial Proteomics.bioRxiv : the preprint server for biology · 2026Article
- FERRET: Framework to Evaluate Robustness in Regulatory Networks Using Heterogeneous Cell Types.bioRxiv : the preprint server for biology · 2026Article
- Mechanisms and therapeutic targets in distant metastasis of lung adenocarcinoma.Signal transduction and targeted therapy · 2026Article
- Trimodal, uncertainty-guided whole-slide framework for genome-scale spatial expression and image-only virtual perturbation in cancer cohorts.Genome medicine · 2026Article
- Multimodal spatial omics: From data acquisition to computational integration.Patterns (New York, N.Y.) · 2026Review
- The Single-Cell Pediatric Cancer Atlas: Data portal and open-source tools for single-cell transcriptomics of pediatric tumors.Cell genomics · 2026Article
- Dissecting human organ development using spatial technologies.Developmental cell · 2026Review
- Foundation models in omics research: a comprehensive survey.Briefings in bioinformatics · 2026Review
- Computational analysis in spatial transcriptomics: methods and perspectives.Briefings in bioinformatics · 2026Review
298 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 20 institutions in 1 country.
Orit Rozenblatt-RosenBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Aviv RegevBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA; Koch Institute for Integrative Cancer Research, Department of Biology, MIT, Cambridge, MA 02139, USA. Electronic address: aregev@broadinstitute.org.
Philipp OberdoerfferDivision of Cancer Biology, National Cancer Institute, NIH, Rockville, MD 20850, USA.
Tal NawyComputational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Anna HupalowskaBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Jennifer E RoodBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Orr AshenbergBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Ethan CeramiDepartment of Data Sciences, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Robert J CoffeyDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Emek DemirDepartment of Molecular and Medical Genetics, School of Medicine, Oregon Health & Science University, Portland, OR 97239, USA.
Li DingDepartment of Medicine, McDonnell Genome Institute, and Siteman Cancer Center, Washington University in St. Louis, Saint Louis, MO 63108, USA.
Edward D EsplinDepartment of Genetics, Stanford School of Medicine, Stanford, CA 94305, USA.
James M FordDepartment of Genetics, Stanford School of Medicine, Stanford, CA 94305, USA; Department of Medicine, Oncology Division, Stanford University School of Medicine, Stanford, CA 94305, USA.
Jeremy GoecksComputational Biology Program, Oregon Health and Science University, OR 97201, USA.
Sharmistha GhoshDivision of Cancer Prevention, National Cancer Institute, NIH, Rockville, MD 20850, USA.
Joe W GrayCenter for Spatial Systems Biomedicine, Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR 97201, USA.
Justin GuinneySage Bionetworks, Seattle, WA 98121, USA; Biomedical Informatics and Medical Education, University of Washington, Seattle, WA 98195, USA.
Sean E HanlonCenter for Strategic Scientific Initiatives, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Shannon K HughesDivision of Cancer Biology, National Cancer Institute, NIH, Rockville, MD 20850, USA.
E Shelley HwangDepartment of Surgery, Duke University School of Medicine, Durham, NC 27710, USA; Women's Cancer Program, Duke Cancer Institute, Duke University, Durham, NC 27710, USA.
Christine A Iacobuzio-DonahueDavid M. Rubenstein Center for Pancreatic Cancer Research, Human Oncology and Pathogenesis Program, and Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Judit Jané-ValbuenaBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Bruce E JohnsonDepartment of Medical Oncology and Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital, 450 Brookline Avenue, Boston, MA 02215, USA.
Ken S LauDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Tracy LivelyDivision of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Rockville, MD 20850, USA.
Sarah A MazzilliDepartment of Medicine, Division of Computational Biomedicine, Boston University School of Medicine, Boston, MA 02118, USA.
Dana Pe'erComputational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Sandro SantagataLudwig Center for Cancer Research and Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Alex K ShalekBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Institute for Medical Engineering and Science, Department of Chemistry, and Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA 02139, USA; Ragon Institute of Massachusetts General Hospital, MIT and Harvard University, Cambridge, MA 02139, USA; Division of Health Sciences and Technology, Harvard Medical School, Boston, MA 02115, USA; Department of Immunology, Massachusetts General Hospital, Boston, MA 02114, USA.
Denis SchapiroBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Ludwig Center for Cancer Research and Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.
Michael P SnyderDepartment of Genetics, Stanford School of Medicine, Stanford, CA 94305, USA.
Peter K SorgerLudwig Center for Cancer Research and Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.
Avrum E SpiraDepartment of Medicine, Division of Computational Biomedicine, Boston University School of Medicine, Boston, MA 02118, USA; Johnson & Johnson, Cambridge, MA 02142, USA.
Sudhir SrivastavaDivision of Cancer Prevention, National Cancer Institute, NIH, Rockville, MD 20850, USA.
Kai TanDivision of Oncology and Center for Childhood Cancer Research, 4004 CTRB, Children's Hospital of Philadelphia, 3501 Civic Center Boulevard, Philadelphia, PA 19104, USA; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Robert B WestDepartment of Pathology, Stanford School of Medicine, Stanford, CA 94305, USA.
Elizabeth H WilliamsDepartment of Data Sciences, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Present address: Foundation Medicine, Cambridge, MA 02141, USA.
Human Tumor Atlas Network
Broad Institute · USStanford Medicine · USNational Cancer Institute · USMemorial Sloan Kettering Cancer Center · USOregon Health & Science University · USFoundation Medicine (United States)Dana-Farber Cancer Institute · USVanderbilt University Medical Center · USBoston University · USBrigham and Women's Hospital · USCenter for Cancer Research · USDuke University · USStanford University · USUniversity of Pennsylvania · USUniversity of Washington · USCenter for Systems Biology · USHarvard University · USHoward Hughes Medical Institute · USJames S. McDonnell Foundation · USRagon Institute of MGH, MIT and Harvard · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MWomen's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI DONNA NIEDZWIECKI · 1985 to 2026
$174.8MWashington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0MINSTITUTIONAL TRAINING GRANT IN GENOME SCIENCET32HG000044 · NHGRI · STANFORD UNIVERSITY · PI MICHAEL P. SNYDER · 1995 to 2026
$32.2MTranslational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9MHuman Tumor Atlas Network: Data Coordinating Center SupplementU24CA233243 · NCI · DANA-FARBER CANCER INST · PI ROBERT C GENTLEMAN, Nikolaus Schultz · 2018 to 2026
$29.1MVanderbilt-Ingram Cancer Center SPORE in Gastrointestinal CancerP50CA236733 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STEPHEN W. FESIK · 2019 to 2026
$19.6MThe Cellular Geography of Therapeutic Resistance in CancerU2CCA233195 · NCI · DANA-FARBER CANCER INST · PI JOHNSON, BRUCE E. · 2018 to 2023
$13.7MData Analysis UnitU2CCA233285 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI TAN, KAI · 2018 to 2023
$13.2MWashington University PDX Development and Trial Center - Evaluation of Abemaciclib in Combination with Olaparib in Ovarian Cancer and Breast Cancer Patient-derived Xenograft ModelsU54CA224083 · NCI · WASHINGTON UNIVERSITY · PI Li Ding · 2017 to 2026
$13.0MTransition to Metastatic State: Lung Cancer, Pancreatic Cancer and Brain MetastasisU2CCA233284 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI PE'ER, DANA · 2018 to 2022
$12.9MHoward Hughes Medical InstituteNCATS NIH HHS L30 TR000589NCI NIH HHS HHSN261201500003INCI NIH HHS K08 CA237732NCI NIH HHS K08 CA237871NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA014236NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA091842NCI NIH HHS P50 CA236733NCI NIH HHS R01 CA245499NCI NIH HHS R35 CA197570NCI NIH HHS R35 CA220508NCI NIH HHS R37 CA219697NCI NIH HHS T32 CA207021NCI NIH HHS U01 CA235482NCI NIH HHS U24 CA231877NCI NIH HHS U24 CA233243NCI NIH HHS U2C CA233195NCI NIH HHS U2C CA233238NCI NIH HHS U2C CA233254NCI NIH HHS U2C CA233262NCI NIH HHS U2C CA233280NCI NIH HHS U2C CA233284NCI NIH HHS U2C CA233285NCI NIH HHS U2C CA233291NCI NIH HHS U2C CA233303NCI NIH HHS U2C CA233311NCI NIH HHS U54 CA224083NHGRI NIH HHS T32 HG000044NIDDK NIH HHS P30 DK058404NIH HHS R24 OD024624
Abstract
Crucial transitions in cancer-including tumor initiation, local expansion, metastasis, and therapeutic resistance-involve complex interactions between cells within the dynamic tumor ecosystem. Transformative single-cell genomics technologies and spatial multiplex in situ methods now provide an opportunity to interrogate this complexity at unprecedented resolution. The Human Tumor Atlas Network (HTAN), part of the National Cancer Institute (NCI) Cancer Moonshot Initiative, will establish a clinical, experimental, computational, and organizational framework to generate informative and accessible three-dimensional atlases of cancer transitions for a diverse set of tumor types. This effort complements both ongoing efforts to map healthy organs and previous large-scale cancer genomics approaches focused on bulk sequencing at a single point in time. Generating single-cell, multiparametric, longitudinal atlases and integrating them with clinical outcomes should help identify novel predictive biomarkers and features as well as therapeutically relevant cell types, cell states, and cellular interactions across transitions. The resulting tumor atlases should have a profound impact on our understanding of cancer biology and have the potential to improve cancer detection, prevention, and therapeutic discovery for better precision-medicine treatments of cancer patients and those at risk for cancer.
Indexed as
Atlases as TopicCell Transformation, NeoplasticGenomicsHumansNeoplasmsPrecision MedicineSingle-Cell AnalysisTumor MicroenvironmentAICancer Moonshotcancer transitionsdata integrationdata visualizationHuman Tumor Atlasmetastasispre-cancerresistancesingle-cell genomicsspatial genomicsspatial imagingtumor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.